Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors

Journal of Neurochemistry

Volumn 71, Issue 6, 1998, Pages 2439-2446

  Maggio, Roberto ^a   Riva, Marco ^b   Vaglini, Francesca ^a   Fornai, Francesco ^a   Molteni, Raffaella ^b   Armogida, Marianna ^a   Racagni, Giorgio ^b,c   Corsini, Giovanni U ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Diethyldithiocarbamate; Methamphetamine; MPTP; Neurotrophic factors; Nicotine; Parkinson's disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DIETHYLDITHIOCARBAMIC ACID; DIZOCILPINE; FIBROBLAST GROWTH FACTOR 2; MECAMYLAMINE; METHAMPHETAMINE; NEUROTROPHIC FACTOR; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CIGARETTE SMOKING; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; IMMUNOCYTOCHEMISTRY; MALE; MESENCEPHALON; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL GROWTH; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031741246     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71062439.x     Document Type: Article

References (42)

1. Aizenman E., Hartnett K. A., and Reynolds J. I. (1990) Oxygen free radicals regulate NMDA receptor function via a redox modulatory site. Neuron 5, 841-846.
2. Aizenman E., Lian-Hong T., and Reynolds I. J. (1991) Effects of nicotinic agonists on the NMDA receptor. Brain Res. 551, 355-357.
3. Asai T., Wanaka A., Kato H., Masana Y., Seo M., and Tohyama M. (1993) Differential expression of two members of FGF receptor gene family. FGFR-1 and FGFR-2 mRNA, in the adult rat central nervous system. Mol. Brain Res. 17, 174-178.
4. Baron J. A. (1986) Cigarette smoking and Parkinson's disease. Neurology 36, 1490-1495.
5. Bean A. J., Elde R., Cao Y., Oellig C., Tamminga C., Goldstein M., Pettersson R. F., and Hokfelt T. (1991) Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human. Proc. Natl. Acad. Sci. USA 88, 10237-10241.
6. Belluardo N., Blum M., Mudo G., Andbjer B., and Fuxe K. (1998) Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel-and diencephalon of the rat. Neuroscience 83, 723-740.
7. Blum M., Wu G., Mudo G., Belluardo N., Andersson K., Agnati F., and Fuxe K. (1996) Chronic continuous infusion of (-)-nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxy-dopamine-lesioned rat. Neuroscience 70, 169-177.
8. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., and Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550.
9. Cintra A., Cao Y., Oellig C., Tinner B., Bortolotti R., Pettersson R. F., and Fuxe K. (1991) Basic FGF is present in dopaminergic neurons of the ventral midbrain of the rat. Neuroreport 2, 597-600.
10. Clarke P. B. S. and Pert A. (1985) Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348, 355-358.
11. 125I bungarotoxin. J. Neurosci. 5, 1307-1315.
12. Conti-Tronconi B. M., McLane K. E., Raftery M. A., Grando S. A., and Protti M. P. (1994) The nicotinic acetylcholine receptor: structure and autoimmune pathology. Crit. Rev. Biochem. Mol. Biol. 29, 69-123.
13. Corsini G. U., Pintus S., Chiueh C. C., Weiss J. F., and Kopin I. J. (1985) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur. J. Pharmacol. 119, 127-128.
14. Ehringer H. and Hornykiewicz O. (1960) Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38, 1236-1239.
15. El-Bizri H. and Clarke P. B. S. (1994) Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br. J. Pharmacol. 111, 406-413.
16. Fornai F., Vaglini F., Maggio R., Bonuccelli U., and Corsini G. U. (1996) Excitatory amino acids and MPTP toxicity. Adv. Neurol. 69, 167-176.
17. Galzi J. L. and Changeux J. P. (1995) Neuronal nicotinic receptors: molecular organization and regulations. Neuropharmacology 34, 563-582.
18. Giovanni A., Sieber B. A., Heikkila R. E., and Sonsalla P. K. (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1-2-3-6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257, 691-697.
19. 3H] dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59, 848-856.
20. Hefti F. J. (1994) Neurotrophic factor therapy for nervous system degenerative diseases. Neurobiology 25, 1418-1435.
21. Hotchkiss A. J. and Gibb J. W. (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214, 257-262.
22. Kiba H. and Jayaraman A. (1994) Nicotine induced c-fos expression in the striatum is mediated mostly by dopamine D1 receptor and is dependent on NMDA stimulation. Mol. Brain Res. 23, 1-13.
23. Langston J. W., Ballard P.A., Tetrud J. W., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
24. Maggio R., Riva M., Vaglini F., Fornai F., Racagni G., and Corsini G. U. (1997) Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J. Neural Transm. 104, 1113-1123.
25. Marin P., Maus M., Desagher S., Glowinski J., and Prémont J. (1994) Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport 5, 1977-1980.
26. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., and Herkenham M. A. (1984) Intrancuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464-467.
27. McGeer E. G., Singh E. A., and McGeer P. L. (1992) Apparent anterograde transport of basic tibroblast growth factor in the rat nigrostriatal dopamine system. Neurosci. Lett. 148, 31-33.
28. Morelli M., Fenu S., Pinna A., and Di Chiara G. (1992) Opposite effects of NMDA receptor blockade on dopaminergic D1-and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J. Pharmacol. Exp. Ther. 260, 402-408.
29. Morens D. M., Grandinetti A., Reed D., White L. R., and Ross G. W. (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45, 1041-1051.
30. Muraki A., Koyama T., Nakayama M., Ohmori T., and Yamashita I. (1992) MK-801, a non-competitive antagonist of NMDA receptor, prevents methamphetamine-induced decrease of striatal dopamine uptake sites in the rat striatum. Neurosci. Lett. 136, 39-42.
31. Otto D. and Unsicker K. (1990) Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10, 1912-1921.
32. Rapier C., Lunt G. G., and Wonnacott S. (1988) Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. J. Neurochem. 50, 1123-1130.
33. Sidman R. L., Angevine J. B. Jr., and Taber Pierce E. (1971) Atlas of the Mouse Brain and Spinal Cord. Harvard University Press, Cambridge, Massachusetts.
34. 3H] dopamine release from rat striatal synaptosomes. J. Neurochem. 67, 163-170.
35. Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
36. Sonsalla P. K., Riordan D. E., and Heikkila R. E. (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256, 506-512.
37. Tooyama I., Kawamata T., Walker D., Yamada T., Hanai K., Kimura H., Iwane M., Igarashi K., McGeer E. G., and McGeer P. L. (1993) High molecular weight basic fibroblast growth factor-like protein is localized to a subpopulation of mesencephalic dopaminergic neurons in the rat brain. Neurology 43, 372-376.
38. Vaglini F., Fascetti F., Fornai F., Maggio R., and Corsini G. U. (1994) (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res. 668, 194-203.
39. Vaglini F., Pardini C., Cavalletti M., Maggio R., and Corsini G. U. (1995) L-Deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. Brain Res. 674, 127-132.
40. Wagner G. C., Ricaurte G. A., Seiden E. S., Schuster C. R., Miller J. M., and Westley J. (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151-160.
41. Wanaka A., Johnson E. M., and Milbrandt J. (1990) Localization of FGF receptor mRNA in the adult rat central nervous system by in situ hybridization. Neuron 5, 267-281.
42. Wonnacott S., Drasdo A., Sanderson E., and Rowell P. (1990) Presynaptic nicotinic receptors and the modulation of transmitter release. Ciba Found. Symp. 152, 87-101.